HC Wainwright Has Negative Outlook for RYTM Q1 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Equities research analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for Rhythm Pharmaceuticals in a research report issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.74) per share for the quarter, down from their prior forecast of ($0.68). HC Wainwright currently has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q2 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.87) EPS and Q1 2026 earnings at ($0.60) EPS.

RYTM has been the topic of a number of other reports. Oppenheimer initiated coverage on Rhythm Pharmaceuticals in a research note on Friday, December 20th. They issued an “outperform” rating and a $76.00 price objective on the stock. Stifel Nicolaus started coverage on Rhythm Pharmaceuticals in a research note on Wednesday, March 5th. They issued a “buy” rating and a $78.00 price target on the stock. Canaccord Genuity Group raised their price objective on shares of Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. JMP Securities reiterated a “market outperform” rating and set a $75.00 target price on shares of Rhythm Pharmaceuticals in a research report on Monday, December 23rd. Finally, Morgan Stanley restated an “overweight” rating and issued a $72.00 price target on shares of Rhythm Pharmaceuticals in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $69.46.

Rhythm Pharmaceuticals Stock Down 1.5 %

RYTM stock opened at $52.91 on Wednesday. The company’s fifty day simple moving average is $55.28 and its 200 day simple moving average is $54.99. Rhythm Pharmaceuticals has a 12-month low of $35.17 and a 12-month high of $68.58. The firm has a market cap of $3.35 billion, a price-to-earnings ratio of -12.22 and a beta of 2.30.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The firm had revenue of $41.83 million during the quarter, compared to analyst estimates of $38.48 million.

Insider Activity at Rhythm Pharmaceuticals

In other news, insider Joseph Shulman sold 1,281 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total value of $76,129.83. Following the transaction, the insider now owns 2,657 shares in the company, valued at $157,905.51. This trade represents a 32.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Christopher Paul German sold 635 shares of the company’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total value of $36,334.70. Following the sale, the chief accounting officer now owns 2,070 shares of the company’s stock, valued at $118,445.40. This trade represents a 23.48 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 108,131 shares of company stock valued at $5,781,098. 5.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. SRS Capital Advisors Inc. increased its stake in Rhythm Pharmaceuticals by 740.7% in the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock valued at $25,000 after buying an additional 400 shares during the last quarter. Raleigh Capital Management Inc. bought a new position in shares of Rhythm Pharmaceuticals in the fourth quarter valued at approximately $28,000. SBI Securities Co. Ltd. purchased a new stake in shares of Rhythm Pharmaceuticals during the fourth quarter valued at approximately $37,000. R Squared Ltd bought a new stake in Rhythm Pharmaceuticals during the fourth quarter worth $44,000. Finally, State of Wyoming purchased a new position in Rhythm Pharmaceuticals in the fourth quarter worth $61,000.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.